Evista raloxifene: Additional Phase III data

Additional data from the double-blind, international Phase III STAR trial in 19,490 evaluable post-menopausal women with an increased risk of breast cancer showed that Evista reduced the risk of invasive breast cancer by about 38% vs. 50% for tamoxifen after 81 months of follow-up. Specifically, there were 310 cases of invasive breast cancer in Evista-treated patients (n=9,754) compared with 247 cases in tamoxifen-treated patients (n=9,736). Data were presented at the American Association for Cancer Research meeting in Washington and published in Cancer Prevention Research. ...